Full-Time

Medical Science Liaison/Senior Medical Science Liaison

Coherus BioSciences

Coherus BioSciences

201-500 employees

Develops and commercializes biosimilar biologics

Compensation Overview

$170k - $240k/yr

United States

In Person

PharmD, PhD, MD

Category
Biology & Biotech (1)

Get referred to Coherus BioSciences

See people who can refer or advise you

Requirements
  • An advanced degree (MD, DO, Ph.D., Pharm D) is preferred; NP and PA degrees with strong relevant clinical experience will be considered
  • A minimum of 2 years previous Medical Science Liaison experience in oncology (with head and neck cancer, liver cancer and/or gastrointestinal cancer preferred)
  • For Senior Medical Science Liaison, a minimum of 3-5 years of previous MSL experience with demonstrated track record of leadership in the MSL role (mentoring others, leading by example, teaching, training, and modeling MSL responsibilities)
  • Ability to travel, locally and regionally, up to 60% with overnight stays
  • Excellent communication (oral and written) and presentation skills
Responsibilities
  • Establish Coherus Oncology as a leading innovative oncology company focused on developing best-in-class medicines that overcome immune resistance in cancer.
  • Develop, track, and execute key opinion leader engagement plans to identify, develop, and maintain long-term collaborative relationships with KOLs within the assigned region.
  • Maintain clinical, scientific and technical expertise in areas of oncology relevant to Coherus products and pipeline.
  • Deliver high-quality, non-promotional scientific exchange regarding company products, pipeline assets, and relevant disease areas.
  • Present clinical value proposition to payers and regional accounts payer formulary decisions.
  • Engage in continuous learning within the therapeutic areas represented and actively attend and participate in upskilling programs related to assigned molecules, products, disease states and relevant business topics.
  • Heighten medical affairs presence and visibility by leading individual projects and initiatives.
  • Collaborate with medical affairs, clinical development, and commercial teams, serving as a Coherus resource to healthcare professionals, large group medical practices, payers and formulary decision makers.
  • Provide medical/clinical teams with feedback and insights from interactions with KOLs and investigators.
  • Respond to and document unsolicited requests for information on Coherus products and clinical programs.
  • Participate in/support the training of Coherus field and home office employees.
  • Facilitate research collaborations such as Real-World Data generation and investigator sponsored trials with key investigators.
  • Represent the company at medical meetings through Medical Affairs’ Medical Booth coverage and other related activities.
  • Engage in speaker identification, training and evaluation and provide support for advisory board meetings as requested.
  • Collaborate with Market Access and Commercial colleagues for thought leader and institutional engagement where appropriate.
  • Support internal requests for dossier review and comment, medical review/consideration of potential business development opportunities and other unique projects as requested.
  • Adhere to corporate standard operating procedures and ensure vigilant compliance with relevant legal and regulatory guidelines governing scientific interactions with physicians and healthcare professionals across all activities, including those related to clinical trials, scientific interactions with internal and external groups, and responses to unsolicited requests for medical/scientific information
Desired Qualifications
  • Experience as a Senior Medical Science Liaison with leadership responsibilities including mentoring MSLs and leading projects
  • Knowledge of payer formulary processes and experience engaging payers strongly preferred
  • Familiarity with Real-World Data generation and investigator sponsored trials
  • Experience working with payers or formulary committees is strongly preferred
  • Demonstrated ability to manage multiple projects independently in a cross-functional environment
  • Cross-functional collaboration and strong internal stakeholder engagement abilities
  • Knowledge of FDA requirements and PhRMA Code, including regulations governing compliant scientific exchange

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines. These products are created through biotechnology to match the safety and effectiveness of the original biologics while offering lower prices. Coherus’ products are designed to provide patients and healthcare systems with more affordable access to essential biologic treatments and to offset rising healthcare costs. The company differentiates itself by focusing on high-quality biosimilars and a rigorous regulatory pathway to ensure similar efficacy and safety to the originals, enabling broader adoption among providers, hospitals, and patients. Its goal is to improve patient lives by expanding access to life-changing biologic medicines and making treatments more affordable.

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Get referred to Coherus BioSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 debt refinancing extended maturities to 2031 and lowered interest burden.
  • June 2026 Zumutor collaboration broadens LOQTORZI combinations into multiple solid tumors.
  • Second-quarter 2026 results and 2025 sales growth showed LOQTORZI traction after the biosimilar exit.

What critics are saying

  • LOQTORZI depends on nasopharyngeal carcinoma; weak expansion stalls 2028 revenue targets.
  • Tagmokitug and casdozokitug remain clinical-stage; a failed 2026 readout crushes valuation.
  • If LOQTORZI uptake disappoints, Coherus burns cash and risks another dilutive financing.

What makes Coherus BioSciences unique

  • LOQTORZI gives Coherus a commercial oncology franchise, not a pure biosimilar story.
  • Coherus owns U.S. rights to toripalimab and combinations like Tagmokitug and casdozokitug.
  • Management exited biosimilars in 2025, concentrating capital on novel immuno-oncology development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

-1%

2 year growth

-1%
Minichart
Aug 17th, 2026
Coherus Oncology secures $55M term loan, extends debt maturity to 2031

Coherus Oncology has secured a $55 million senior secured term loan to refinance existing debt and extend its maturity timeline. The company signed the agreement with Innovatus Life Sciences Lending Fund I and other lenders on 12 August 2026, drawing the full amount two days later. The new loan matures in August 2031, extending the previous May 2029 deadline beyond anticipated product launches. It carries a floating interest rate of 4.15% plus the greater of Prime Rate or 6.75%, lower than the prior facility's 8.0% plus three-month SOFR. The facility includes a 36-month interest-only period, potentially extendable to 48 months upon meeting revenue and market capitalisation targets. Additional tranches of $25 million and $20 million remain available under certain conditions.

BioPatrika
Jun 24th, 2026
Coherus and Zumutor launch Phase 1 trial of ZM008 and LOQTORZI combination therapy.

Coherus and Zumutor launch Phase 1 trial of ZM008 and LOQTORZI combination therapy. June 24, 2026 Coherus and Zumutor Biologics announce clinical collaboration to evaluate ZM008 in combination with LOQTORZI(R)(toripalimab-tpzi). - First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor. Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors. "We are excited to partner with Zumutor Biologics on the development of LOQTORZI with ZM0008 as a novel combination treatment for cancer patients in this Phase 1 study," said Theresa LaVallee, Ph.D., Chief Scientific and Development Officer at Coherus Oncology. "This collaboration is another example of our strategy to expand potential LOQTORZI indications beyond NPC and strengthen the clinical data package in the US through cost-efficient drug supply agreements, evaluating LOQTORZI with novel mechanisms in prioritized tumor types such as NSCLC, HNSCC, and others." ZM008, discovered using Zumutor's proprietary fully human monoclonal antibody library INABLR(R), has demonstrated a favorable safety profile, with no dose-limiting toxicities or anti-drug antibodies. In an ongoing monotherapy study, ZM008 has shown clinical benefit in metastatic patients previously treated with immune checkpoint inhibitors. Targeting complementary adaptive and innate immune pathways can unlock meaningful clinical benefit, particularly in hard-to-treat "cold tumors" that remain less responsive to current immunotherapies. "This Phase 1 study will evaluate ZM008 in combination with LOQTORZI and will generate key insights into response mechanisms, identify predictive biomarkers, and refine patient selection strategies to accelerate personalized therapies," said Maloy Ghosh, Ph.D., Chief Scientific Officer of Zumutor. The trial will evaluate safety, tolerability, and the recommended dose of ZM008, enrolling up to 45 patients across dose-escalation and expansion cohorts in the United States. "The initiation of combination studies of ZM008 with toripalimab, from Coherus Oncology, represents a pivotal milestone for our lead program," said Kavitha Iyer Rodrigues, CEO of Zumutor Biologics Inc. "Building on encouraging early clinical data, this advancement strengthens our conviction in ZM008's potential to deliver a differentiated and meaningful immunotherapy option for patients with difficult-to-treat cancers and underscores our commitment to accelerating its clinical development." Under the terms of the clinical trial collaboration and supply agreement, Coherus Oncology will provide LOQTORZI to Zumutor, which will be the sponsor of the Phase 1 clinical combination trial. Zumutor and Coherus each retain all commercial rights to their respective compounds, as monotherapies or combination therapies. About Zumutor Biologics Inc. Zumutor Biologics Inc. is a clinical-stage biotechnology company pioneering next-generation immunotherapies by targeting innate immune pathways, with a focus on natural killer (NK) cell checkpoints. Headquartered in Boston, with R&D operations in Bangalore, the company leverages its proprietary INABLR(R) platform-combining high-diversity human antibody libraries with yeast and phage display technologies, to rapidly advance differentiated biologics. Zumutor's lead asset, ZM008, a novel anti-LLT1 antibody, is currently in first-in-human clinical trials in the U.S., with dose expansion planned. The company is also progressing additional pipeline programs targeting NK cell activation pathways with strong oncology potential. Founded in 2015, Zumutor has raised approximately $33 million from a reputable global investor syndicate. Zumutor Contacts Kavitha Iyer Rodrigues: CEO, Zumutor Biologics Inc [email protected] About Coherus Oncology Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 ("PD-1") inhibitor, LOQTORZI(R)(toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company's strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships. Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma. LOQTORZI(R) is a registered trademark of Coherus Oncology, Inc.

Yahoo Finance
Mar 10th, 2026
Coherus Oncology doubles LOQTORZI revenue to $41M, slashes debt by 90% to $39M

Coherus Oncology has reported strong revenue growth for 2025, with its drug LOQTORZI achieving net revenue of $40.8 million, a 113% increase from $19.1 million in 2024. Fourth-quarter revenue reached $12.4 million, marking an 11% growth over the third quarter. The company significantly improved its financial position by reducing debt by over 90%, from $480 million to $38.8 million by year-end 2025. This resulted in interest cost savings of over $15 million. The firm also cut headcount by 35% and reduced selling, general and administrative expenses to $23.6 million in Q4 from $29.6 million the previous year. Coherus ended 2025 with $172.1 million in cash and investments whilst developing two promising product candidates, Tagmokitug and casdozokitug.

Yahoo Finance
Mar 8th, 2026
Coherus cuts debt 90%, LOQTORZI sales double in 2025, eyes $175M annual run rate by 2028

Coherus Oncology has reduced its debt by approximately 90%, cutting it from $480 million to $3.7 million in senior secured debt, whilst adding $250 million to its balance sheet through biosimilar asset divestitures following its 2023 Surface Oncology acquisition. The company reported accelerating sales of LOQTORZI, its PD-1 therapy for nasopharyngeal carcinoma, with 2025 sales doubling from 2024's $19 million. Management expects quarterly sales to reach $15 million to $16 million in 2026, covering the commercial team's costs, and projects a long-term run rate of roughly $175 million annually by 2028. Coherus aims to achieve cash-flow breakeven, excluding clinical trial costs, when quarterly sales exceed $30 million. The company has scheduled clinical data readouts for two pipeline assets in 2026.

MarketScreener
Feb 13th, 2026
Coherus Oncology prices $50M public offering at $1.75 per share to fund LOQTORZI commercialisation

Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share. The company expects to raise approximately $50.1 million in gross proceeds before underwriting discounts and expenses. The offering includes a 30-day option for underwriters to purchase an additional 4.29 million shares. The transaction is expected to close on 17 February 2026. Coherus plans to use the net proceeds to support commercialisation of LOQTORZI, continue clinical development of product candidates, and for working capital and general corporate purposes. The commercial-stage oncology company has an approved PD-1 inhibitor and a pipeline targeting liver, prostate, head and neck, and colorectal cancers. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners.